Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma
Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma
复制标题
重度哮喘患者上、下气道嗜酸性粒细胞炎症与奥马珠单抗反应的关系
DOI：
10.1080/02770903.2018.1541357
复制
发表时间：
2020
影响因子：
1.9
通讯作者：
Kikuchi Toshiaki
中科院分区：
文献类型：
--
作者：
Kurokawa Makoto;Koya Toshiyuki;Takeuchi Hiroyuki;Hayashi Masachika;Sakagami Takuro;Ishioka Kojiro;Gon Yasuhiro;Hasegawa Takashi;Kikuchi Toshiaki
背景：抗免疫球蛋白E的单抗奥马珠单抗用于治疗重症哮喘，具有改善呼吸道炎症的潜力。目的：探讨上、下呼吸道炎症反应与奥马珠单抗治疗反应的关系。方法：采用全球疗效评价法评价16例重症哮喘患者应用奥马珠单抗治疗的疗效。观察治疗前和治疗4个月后症状积分、短效β激动剂使用、肺功能、生物标志物、CT扫描和鼻粘膜病理改变。结果：以呼出一氧化氮(FeNO)和痰嗜酸粒细胞百分比作为下呼吸道炎症指标时，鼻粘膜CD20B细胞、肥大细胞和嗜酸性粒细胞计数呈正相关。16例重症哮喘患者中有12例哮喘症状改善。在使用奥马珠单抗之前，鼻腔组织中的FeNO和嗜酸性粒细胞水平是哮喘治疗反应的预测因子。结论：这些发现提示重度哮喘患者存在异质性。此外，与对奥马珠单抗的反应相关的、导致哮喘症状改善的表型包括上呼吸道嗜酸性粒细胞增多症和高FeNO水平。
Background: The anti-immunoglobulin E monoclonal antibody, omalizumab, is used to treat severe asthma and has the potential to ameliorate airway inflammation. However, the effect of omalizumab in ameliorating upper airway inflammation has not been fully elucidated.Objective: We investigated the association of upper and lower airway inflammation with the response to omalizumab treatment.Methods: We used the Global Evaluation of Treatment Effectiveness to assess the efficacy of omalizumab in treating 16 patients with severe asthma. We also investigated the symptom score, short-acting β-agonist inhaler use, pulmonary function, biomarkers, computed tomography scans, and nasal mucosa pathology at omalizumab initiation and after four months of treatment.Results: When the fraction of exhaled nitric oxide (FeNO) and the percentage of sputum eosinophil were used as indicators of lower airway inflammation, positive correlations were found between CD20 B-cell, mast cell, and eosinophil counts in the nasal mucosa. Improved asthma symptoms were observed in 12 of the 16 severe asthma cases. The FeNO and eosinophil levels in the nasal tissue, prior to the administration of omalizumab were predictors of the response to asthma treatment.Conclusions: These findings suggest heterogeneity among people with severe asthma. In addition, the phenotype associated with response to omalizumab, leading to improvement in asthma symptoms, comprises upper airway eosinophilia and high FeNO levels.
登录
查看更多内容
DOI：
--
发表时间：
2004
期刊：
The Journal of allergy and clinical immunology
影响因子：
--
作者：
L. Beck;G. V. Marcotte;D. MacGlashan;A. Togias;S. Saini
通讯作者：
L. Beck;G. V. Marcotte;D. MacGlashan;A. Togias;S. Saini
DOI：
10.1164/rccm.200406-710st
发表时间：
2005-04-15
影响因子：
24.7
作者：
American Thoracic Society;European Respiratory Society
通讯作者：
European Respiratory Society
呼出的一氧化氮和鼻类胰蛋白酶与小学生喘息、鼻炎和鼻过敏有关
影响因子：
2.6
作者：
Sofie De Prins;F. Marcucci;L. Sensi;E. Van de Mieroop;V. Nelen;T. Nawrot;G. Schoeters;G. Koppen
通讯作者：
G. Koppen
哮喘受试者中一种痰诱导方法的安全性。
DOI：
10.1164/ajrccm.156.1.9610114
发表时间：
1997
影响因子：
24.7
作者：
H. Wong;J. Fahy
通讯作者：
J. Fahy
影响因子：
4.3
作者：
Bousquet, J.;Rabe, K.;Holgate, S.
通讯作者：
Holgate, S.